T cells play an essential role in anti-F1 mediated rapid protection against bubonic plague

Vaccine

Volumn 29, Issue 40, 2011, Pages 6866-6873

  Levy, Yinon ^a   Flashner, Yehuda ^a   Tidhar, Avital ^a   Zauberman, Ayelet ^a   Aftalion, Moshe ^a   Lazar, Shirley ^a   Gur, David ^a   Shafferman, Avigdor ^a   Mamroud, Emanuelle ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

Complement system; F1; LcrV; Plague; T cells; Y. pestis

Indexed keywords

BACTERIAL VACCINE; F1 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BUBONIC PLAGUE; CELL SURVIVAL; COMPLEMENT SYSTEM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MECHANISM; FEMALE; HUMORAL IMMUNITY; MORTALITY; MOUSE; NEUTROPHIL; NONHUMAN; PLAGUE; PRIORITY JOURNAL; PROVOCATION TEST; SINGLE DRUG DOSE; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; B-LYMPHOCYTES; BACTERIAL PROTEINS; COMPLEMENT SYSTEM PROTEINS; FEMALE; IMMUNITY, HUMORAL; IMMUNIZATION; MICE; NEUTROPHILS; PLAGUE; PLAGUE VACCINE; PORE FORMING CYTOTOXIC PROTEINS; RABBITS; T-LYMPHOCYTES; YERSINIA PESTIS;

EID: 80052335436     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.07.059     Document Type: Article

References (44)

1. Butler T. Plague and other Yersian infections 1983, Plenum press, New York.
2. Inglesby T.V., Dennis D.T., Henderson D.A., Bartlett J.G., Ascher M.S., Eitzen E., et al. Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense. JAMA 2000, 283(May (17)):2281-2290.
3. Galimand M., Guiyoule A., Gerbaud G., Rasoamanana B., Chanteau S., Carniel E., et al. Multidrug resistance in Yersinia pestis mediated by a transferable plasmid. N Engl J Med 1997, 337(September (10)):677-680.
4. Williamson E.D., Flick-Smith H.C., LeButt C., Rowland C.A., Jones S.M., Waters E.L., et al. Human immune response to a plague vaccine comprising recombinant F1 and V antigens. Infect Immun 2005, 73:3598-3608.
5. Smiley S.T Current challenges in the development of vaccines for pneumonic plague. Expert Rev Vaccines 2008, 7(March (2)):209-221.
6. Du Y., Rosqvist R., Forsberg A. Role of fraction 1 antigen of Yersinia pestis in inhibition of phagocytosis. Infect Immun 2002, 70(March (3)):1453-1460.
7. Skrzypek E., Straley S.C. Differential effects of deletions in lcrV on secretion of V-antigen, regulation of the low-Ca++ response and virulence of Yersinia pestis. J Bacteriol 1995, 177:2530-2542.
8. Fields K.A., Nilles M.L., Cowan C., Straley S.C. Virulence role of Vantigen of Yersinia pestis at the bacterial surface. Infect Immun 1999, 67:5395-5408.
9. Mueller C.A., Broz P., Muller S.A., Ringler P., Erne-Brand F., Sorg I., et al. The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles. Science 2005, 310(October (5748)):674-676.
10. Flashner Y., Fisher M., Tidhar A., Mechaly A., Gur D., Halperin G., et al. The search for early markers of plague: evidence for accumulation of soluble Yersinia pestis LcrV in bubonic and pneumonic mouse models of disease. FEMS Immunol Med Microbiol 2010, (April).
11. Powell B.S., Andrews G.P., Enama J.T., Jendrek S., Bolt C., Worsham P., et al. Design and testing for a nontagged F1-V fusion protein as vaccine antigen against bubonic and pneumonic plague. Biotechnol Prog 2005, 21(September-October (5)):1490-1510.
12. Jones S.M., Day F., Stagg A.J., Williamson D.E. Protection conferred by a fully recombinant sub-unit vaccine against Yersinia pestis in male and female mice of four inbred strains. Vaccine 2001, 19:358-366.
13. Andrews G.P., Heath D.G., Anderson G.W., Welkos S.L., Friedlander A.M. Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge. Infect Immun 1996, 64(June (6)):2180-2187.
14. Williamson E.D., Stagg A.J., Eley S.M., Taylor R., Green M., Jones S.M., et al. Kinetics of the immune response to the (F1+V) vaccine in models of bubonic and pneumonic plague. Vaccine 2007, 25(January (6)):1142-1148.
15. Williamson D.E., Eley S.M., Stagg A.J., Green M., Russell P., Titball R. A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 2000, 19(4-5):566-571.
16. Holzman T., Levy Y., Marcus D., Flashner Y., Mamroud E., Cohen S., et al. Production and purification of high molecular weight oligomers of Yersinia pestis F1 capsular antigen released by high cell density culture of recombinant Escherichia coli cells carrying the caf1 operon. Microbial Cell Factories 2006, 5(Suppl. I):98.
17. Leary S.E., Williamson E.D., Griffin K.F., Russell P., Eley S.M., Titball R.W. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague. Infect Immun 1995, 63(August (8)):2854-2858.
18. Petsch D., Anspach F.B. Endotoxin removal from protein solutions. J Biotechnol 2000, 76:97-119.
19. Flashner Y., Grosfeld H., Mamroud E., Levy Y., Tidhar A., Fass R., et al. Combined caf1 and lcrV genetic immunization can provide protection against very high challenge dose of Y. pestis 2006.
20. Zauberman A., Cohen S., Levy Y., Halperin G., Lazar S., Velan B., et al. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague. Vaccine 2008, 26(March (13)):1616-1625.
21. Heine H.S., Louie A., Sorgel F., Bassett J., Miller L., Sullivan L.J., et al. Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague. J Infect Dis 2007, 196(September (5)):782-787.
22. Tidhar A., Flashner Y., Cohen S., Levi Y., Zauberman A., Gur D., et al. The NlpD lipoprotein is a novel Yersinia pestis virulence factor essential for the development of plague. PLoS One 2009, 4(9):e7023.
23. Kitamura D., Roes J., Kuhn R., Rajewsky K. A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin mu chain gene. Nature 1991, 350(April (6317)):423-426.
24. Parent M.A., Berggren K.N., Kummer L.W., Wilhelm L.B., Szaba F.M., Mullarky I.K., et al. Cell-mediated protection against pulmonary Yersinia pestis infection. Infect Immun 2005, 73:7304-7310.
25. Zauberman A., Tidhar A., Levy Y., Bar-Haim E., Halperin G., Flashner Y., et al. Yersinia pestis endowed with increased cytotoxicity is avirulent in a bubonic plague model and induces rapid protection against pneumonic plague. PLoS One 2009, 4(6):e5938.
26. Wessels M.R., Butko P., Ma M., Warren H.B., Lage A., Carroll M.C. Studies of group B streptococcal infection in mice deficient in complement C3 or C4 demonstrate an essential role for complement in both innate and acquired immunity. Proc Natl Acad Sci USA 1995, 92:11490-11494.
27. Williamson E.D., Vesey P.M., Gillhespy K.J., Eley S.M., Green M., Titball R.W. An IgG1 titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol 1999, 116(April (1)):107-114.
28. Titball R.W., Williamson E.D. Yersinia pestis (plague) vaccines. Expert Opin Biol Ther 2004, 4:965-973.
29. Kearney J. Innate-like B cells. Springer Semin Immunopathol 2005, 26:377-383.
30. Cole L.E., Yang Y., Elkins K.L., Fernandez E.T., Qureshi N., Shlomchik M.J., et al. Antigen-specific B-1a antibodies induced by Francisella tularensis LPS provide long-term protection against F. tularensis LVS challenge. Proc Natl Acad Sci USA 2009, 106(March (11)):4343-4348.
31. Nakajima R., Motin V.L., Brubaker R.R. Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. Infect Immun 1995, 63(8):3021-3029.
32. Anderson G.W., Worsham P., Bolt C., Andrews G.P., Welkos S., Friedlander A.M., et al. Protection of mice from fatal bubonic and pneumonic plague by passive immunization with monoclonal antibodies against the F1 protein of Yersinia pestis. Am J Trop Med Hyg 1997, 56(4):471-473.
33. Hill J., Copse C., Leary S., Stagg A.J., Williamson E.D., Titball R.W. Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis. Infect Immun 2003, 71(April (4)):2234-2238.
34. Levy Y., Flashner Y., Zauberman A., Tidhar A., Aftalion M., Lazar S., et al. Protection against plague afforded by treatment with polyclonal αLcrV and αF1 antibodies. The challenge of highly pathogenic microorganisms 2010, 269-274. Springer, Eilat. A. Shafferman, A. Ordentlich, B. Velan (Eds.).
35. Cornelius C.A., Quenee L.E., Elli D., Ciletti N.A., Schneewind O. Yersinia pestis IS1541 transposition provides for escape from plague immunity. Infect Immun 2009, 77(May (5)):1807-1816.
36. Bartra S.S., Styer K.L., O'Bryant D.M., Nilles M.L., Hinnebusch B.J., Aballay A., et al. Resistance of Yersinia pestis to complement-dependent killing is mediated by the Ail outer membrane protein. Infect Immun 2008, 76(February (2)):612-622.
37. Cowan C., Philipovskiy A.V., Wulff-Strobel C.R., Ye Z., Straley S.C. Anti-LcrV antibody inhibits delivery of Yops by Yersinia pestis KIM5 by directly promoting phagocytosis. Infect Immun 2005, 73(September (9)):6127-6137.
38. Eisele N.A., Lee-Lewis H., Besch-Williford C., Brown C.R., Anderson D.M. Chemokine receptor CXCR2 mediates bacterial clearance rather than neutrophil recruitment in a murine model of pneumonic plague. Am J Pathol 2011, 178(March (3)):1190-1200.
39. Philipovskiy A.V., Smiley S.T. Vaccination with live Yersinia pestis primes CD4 and CD8 T cells that synergistically protect against lethal pulmonary Y. pestis infection. Infect Immun 2007, 75:878-885.
40. Wang S., Goguen J.D., Li F., Lu S. Involvement of CD8+T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge. Vaccine 2010, (January).
41. Pujol C., Bliska J.B. The ability to replicate in macrophages is conserved between Yersinia pestis and Yersinia pseudotuberculosis. Infect Immun 2003, 71(October (10)):5892-5899.
42. Straley S.C., Harmon P.A. Growth in mouse peritoneal macrophages of Yersinia pestis lacking established virulence determinants. Infect Immun 1984, 45(September (3)):649-654.
43. Markham R.B., Pier G.B., Schreiber J.R. The role of cytophilic IgG3 antibody in T cell-mediated resistance to infection with the extracellular bacterium Pseudomonas aeruginosa. J Immunol 1991, 146:316-320.
44. Rhinheart-Jones T.R., Fortier A.H., Elkins K.L. Transfer of immunity against lethal murine Francisella infection by specific antibody depends on host gamma interferon and T cells. Infect Immun 1994, 62(August (8)):3129-3137.